Spermidin Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Studie.

Denna dubbelblinda randomiserade placebokontrollerade pilotstudie omfattade 40 friska vuxna över 65 år efter deras tredje vaccindos mot SARS-CoV-2. Deltagarna tog 6 mg oralt spermidin dagligen i 13 veckor. Enligt sammanfattningen tolererades tillskottet väl. Vaccine non-response was common, and non-responders had an immune-senescence signature that included higher p16, mTOR signalling, and γ-H2AX-positive DNA damage in lymphocytes. In this non-responder subgroup, spermidine reversed those features and significantly increased spike-specific IgG secretion, memory B-cell recall responses, and neutralising antibody activity. Single-cell RNA sequencing after treatment showed greater expression of TFEB targets and autophagy-related genes in B cells, alongside increased autophagic flux. The finding is biologically interesting, but it is not a demonstration that spermidine improves vaccine protection, reduces infections, or slows aging. The abstract does not give the number of non-responders, antibody-effect sizes, infection outcomes, or arm-specific numerical results. It also does not state whether similar immune effects occurred in vaccine responders. The applicable claim is narrow: this small study found improved laboratory immune measures in a selected subgroup of older adults after vaccination.

Targeting immune-cell senescence with spermidine may improve vaccine responsiveness in older adults.